These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22066163)

  • 21. Comparative studies of heparin cofactor activity toward antithrombin III and heparin cofactor II, and antithrombin III affinity between low molecular weight heparin and unfractionated heparin.
    Shimotori T; Sakuragawa N
    Semin Thromb Hemost; 1990 Oct; 16 Suppl():71-6. PubMed ID: 1962909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombophilia and venous thromboembolism: implications for testing.
    Cohn DM; Roshani S; Middeldorp S
    Semin Thromb Hemost; 2007 Sep; 33(6):573-81. PubMed ID: 17768689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
    Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical diagnosis of thrombosis and blood coagulation tests].
    Watanabe K
    Rinsho Byori; 1998 Mar; 46(3):235-44. PubMed ID: 9564763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Standardization of the laboratory method for antithrombin activity measurement].
    Okajima K
    Rinsho Byori; 2002 Mar; 50(3):283-6. PubMed ID: 11985057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antithrombin III- and heparin cofactor II-mediated anticoagulant and antiprotease actions of heparin and its synthetic analogues.
    Jeske W; Fareed J
    Semin Thromb Hemost; 1993; 19 Suppl 1():241-7. PubMed ID: 8362268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ability of three global plasma assays to recognize thrombophilia.
    Andresen MS; Abildgaard U; Liestøl S; Sandset PM; Mowinckel MC; Ødegaard OR; Larsen ML; Diep LM
    Thromb Res; 2004; 113(6):411-7. PubMed ID: 15226097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antithrombin III deficiency: when substitute, when heparin? Thrombosis ABC, 3: The role of antithrombin III].
    Stiefelhagen P
    MMW Fortschr Med; 1999 Sep; 141(37):41. PubMed ID: 10897973
    [No Abstract]   [Full Text] [Related]  

  • 29. Laboratory diagnosis of antithrombin and heparin cofactor II deficiency.
    Tollefsen DM
    Semin Thromb Hemost; 1990 Apr; 16(2):162-8. PubMed ID: 2191430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Thrombin, antithrombin, thrombin-antithrombin complex (TAT)].
    Sakata T
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():626-8. PubMed ID: 15658407
    [No Abstract]   [Full Text] [Related]  

  • 31. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology.
    Favaloro EJ; Bonar R; Sioufi J; Wheeler M; Low J; Aboud M; Duncan E; Smith J; Exner T; Lloyd J; Marsden K;
    Semin Thromb Hemost; 2005 Feb; 31(1):49-58. PubMed ID: 15706475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Constitutional thrombophilias: indications of the biological profile and therapeutic consequences].
    Trillot N; Rugeri L; Jude B
    Therapie; 1999; 54(4):413-8. PubMed ID: 10667107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinetic considerations on the physiologic control of thrombin and factor Xa.
    Scully MF
    Semin Thromb Hemost; 1992; 18(2):218-23. PubMed ID: 1631569
    [No Abstract]   [Full Text] [Related]  

  • 34. Transient desialylation in combination with a novel antithrombin deficiency causing a severe and recurrent thrombosis despite anticoagulation therapy.
    Revilla N; de la Morena-Barrio ME; Miñano A; López-Gálvez R; Toderici M; Padilla J; García-Avello Á; Lozano ML; Lefeber DJ; Corral J; Vicente V
    Sci Rep; 2017 Mar; 7():44556. PubMed ID: 28303970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto.
    Okajima K; Ueyama H; Hashimoto Y; Sasaki Y; Matsumoto K; Okabe H; Inoue M; Araki S; Takatsuki K
    Thromb Haemost; 1989 Feb; 61(1):20-4. PubMed ID: 2749590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Role of newly developed technology in blood coagulation disorders].
    Matsuo T
    Rinsho Byori; 2002 May; 50(5):506-12. PubMed ID: 12078050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Laboratory investigation of hypercoagulability.
    Francis JL
    Semin Thromb Hemost; 1998; 24(2):111-26. PubMed ID: 9579632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombophilias: when should we test and how does it help?
    Whitlatch NL; Ortel TL
    Semin Respir Crit Care Med; 2008 Feb; 29(1):25-39. PubMed ID: 18302084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testing for genetic predisposition to venous thrombosis.
    Marques MB
    MLO Med Lab Obs; 2002 Jan; 34(1):8-13; quiz 20-1. PubMed ID: 11828956
    [No Abstract]   [Full Text] [Related]  

  • 40. The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.
    Samama MM
    Thromb Res; 2011 Jun; 127(6):497-504. PubMed ID: 20888031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.